This article is a correction to:
Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach
Yee Kit Tai1,2
Karen Ka Wing Chan1,2Charlene Hui Hua Fong1,2Sharanya Ramanan1,2Jasmine Lye Yee Yap1,2Jocelyn Naixin Yin1,2Yun Sheng Yip3Wei Ren Tan3Angele Pei Fern Koh4
Nguan Soon Tan3,5Ching Wan Chan6,7
Ruby Yun Ju Huang4,8
Jing Ze Li1Jürg Fröhlich1,9,10
Alfredo Franco-Obregón1,2,11,12,13,14*- 1Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
- 2Biolonic Currents Electromagnetic Pulsing Systems Laboratory (BICEPS), National University of Singapore, Singapore, Singapore
- 3Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, Singapore, Singapore
- 4Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
- 5School of Biological Sciences, Nanyang Technological University Singapore, Singapore, Singapore
- 6Division of General Surgery (Breast Surgery), Department of Surgery, National University Hospital, Singapore, Singapore
- 7Division of Surgical Oncology, National University Cancer Institute, Singapore, Singapore
- 8Department of Obstetrics & Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
- 9Fields at Work GmbH, Zürich, Switzerland
- 10Institute of Electromagnetic Fields, ETH Zürich (Swiss Federal Institute of Technology in Zürich), Zürich, Switzerland
- 11Institute for Health Innovation & Technology (iHealthtech), National University of Singapore, Singapore, Singapore
- 12Competence Center for Applied Biotechnology and Molecular Medicine, University of Zürich, Zürich, Switzerland
- 13Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
- 14Healthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
A Corrigendum on:
Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach
By Tai YK, Ramanan S, Chan KKW, Yap JLY, Fong CHH, Yin JN, Tan WR, Koh APF, Tan NS, Yip YS, Chan CW, Huang RYJ, Li JZ, Fröhlich J and Franco-Obregón A (2022) Front. Oncol. 11:783803. doi: 10.3389/fonc.2021.783803
In the original article, there was a nonconsequential error in Figure 1 as published. A file concatenation error occurred within the FACS analysis software that implicated the scatter dot-plots shown in Figure 1C. The corrected Figure 1 appears below.
FIGURE 1
Figure 1 PEMFs synergize with DOX to inhibit tumor growth in vivo. (A) Schematic of PEMF and DOX exposure regimes used on mice hosting patient-derived tumor xenografts. Implanted tumors were allowed to grow for 3 weeks before the initiation of DOX (20 mg/kg) and/or PEMF treatments. Tumor volumes were measured each week while apoptotic cell determination was performed at the end of the study. Each data point represents the mean values from 5 experimental runs derived from the tumors obtained from 5 patients, each of which was equally divided amongst the 5 treatment groups. (B) Changes in tumor volume (mm3) for 5 weeks. (C) Representative scatter dot-plots showing cell populations from dissociated tumors based on Annexin V and propidium iodide staining. (D) Quantification of apoptotic cell percentages obtained using flow cytometry. *p < 0.05, **p < 0.01, and #p < 0.0001. Error bars represent the standard error of the mean.
The associated corrected values that appear in the text of the Results under the subheading “PEMF and Doxorubicin Treatments Act Synergistically to Impair Breast Cancer Tumor Growth In Vivo”, paragraph one, should read “Moreover, the incidence of apoptotic cells increased by +0.55%, +10.2%, and +18% in tumors isolated from control, PEMF-exposed and DOX-treated mice, respectively (Figures 1C, D)”.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: breast cancer, PEMFs, EMT, patient-derived xenograft, chorioallantoic membrane, doxorubicin, TRPC1, chemotherapy
Citation: Tai YK, Chan KKW, Fong CHH, Ramanan S, Yap JLY, Yin JN, Yip YS, Tan WR, Koh APF, Tan NS, Chan CW, Huang RYJ, Li JZ, Fröhlich J and Franco-Obregón A (2022) Corrigendum: Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach. Front. Oncol. 12:892408. doi: 10.3389/fonc.2022.892408
Received: 09 March 2022; Accepted: 31 March 2022;
Published: 20 April 2022.
Edited and reviewed by:
Tarik Smani, Sevilla University, SpainCopyright © 2022 Tai, Chan, Fong, Ramanan, Yap, Yin, Yip, Tan, Koh, Tan, Chan, Huang, Li, Fröhlich and Franco-Obregón. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Alfredo Franco-Obregón, c3VyYWZAbnVzLmVkdS5zZw==